melody432 Wednesday, 04/29/20 01:41:15 PM Re: None Post # of 5724 Evidently mant Australian retail investors believe that a small cap biotech company with a recently approved product should have declining sales and marketing expenses soon after launch. Why they believe this is beyond my meager intellect. Avita's burn rate is lower than many small cap biotechs I've followed, most of which don't even have an approved product. I do believe Covid19 has pushed back timelines, but that's true for at least 90% of business. Like the rest of the market it's going to bounce around for awhile. Shouldn't be news to anyone at this point.